Post by Markus Wagner

The latest Dealroom.co's Healthcare AI map is clearly US-heavy. Europe has fewer companies represented, but the startups that do appear are concentrated in some of the industry's hardest-to-build categories: Isomorphic Labs Axiom Therapeutics Anterior Cradle Nabla Boltz This is particularly evident in AI drug discovery and life sciences, where Europe's position appears much stronger than a simple company count suggests. Isomorphic Labs' $2.1B funding in May is a strong signal that investors are willing to back European companies tackling technically difficult, strategically important problems. If your advantage is science, proprietary data, clinical evidence, or regulated deployment, the opportunity is to make that advantage visible to global investors or buyers. _______________ i5growth / i5invest: Investment Fund, global tech M&A arm, team of 100+, offices in San Francisco, Vienna, Madrid, Berlin, Frankfurt; 200+ exits & strategic partnerships with tech leaders such as Google, Microsoft, Salesforce, Qualcomm, Samsung, Nvidia, Naspers, NBC, … #growth #founders #venturecapital #startups #i5invest